Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...

Medtel announces the appointment of Dr. Kevin Most as Senior Advisor. With over 30 years of healthcare leadership, including 17 years as CMO at Northwestern Medicine Central DuPage Hospital, Dr. Most ...

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

Rakovina Therapeutics Inc., a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, announced the successful achievement of a shortlist ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market ...

"Our air conditioners have been controlling temperature and humidity, but maybe the air conditioners of tomorrow will also ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

'Nasty' Nick was a villain from the start of EastEnders, committing the soap's first murder in the opening episode. The actor ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...